operable NSCLC. Pts are randomized to receive or not receive two courses of neoadjuvant chemotherapy before surgery
Conditions
Interventions
Trade Name: taxotere
Product Name: taxotere
Product Code: L01CD02
Pharmaceutical Form: Intravenous infusion
Trade Name: carboplatin
Product Name: carboplatin
Product Code: L01XA02
Pharmaceutical Form
Sponsors
Jens Benn Sorensen, Dept. oncology, Finsen Centre/National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: NSCLC resectable disease normal organ function Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: abnormal liver-, renal-, or bone marrow function inability to understand the protocol information inability to cooperate with the protocoll treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluate the impact of two courses of neoadjuvant chemotherapy on the survival rate in resectable non-small cell lung cancer;Secondary Objective: time to progression and response rate ;Primary end point(s): survival | — |
Countries
Denmark
Outcome results
None listed